Form 4: OnKure Therapeutics Director Valerie Jansen Acquires 7,650 Stock Options

OnKure Therapeutics, Inc. Director Valerie Malyvanh Jansen reported the acquisition of 7,650 stock options with an exercise price of $2.44, vesting on the earlier of May 28, 2026, or the day prior to the next annual meeting.

Summary

• Valerie Malyvanh Jansen, a Director of OnKure Therapeutics, Inc. (OKUR), acquired 7,650 stock options.
• The transaction occurred on May 28, 2025.
• Each option has an exercise price of $2.44.
• The options grant the right to buy 7,650 shares of Class A Common Stock.
• The options will vest 100% on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders, contingent on Ms. Jansen's continued service.
• The options expire on May 27, 2035.
• Following this transaction, Ms. Jansen beneficially owns 7,650 derivative securities directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal as it aligns the director's interests with shareholder value creation. It's a routine compensation event, not indicative of major operational news, hence a moderately positive score.

Positives

• The acquisition of stock options by a director indicates alignment of interests between the board and shareholders, as the options gain value if the stock price increases.
• The long expiration date of May 27, 2035, provides a significant window for the options to become in-the-money.

Risks

• The value of the stock options is dependent on the future performance of OnKure Therapeutics' stock price; if the stock price does not exceed the exercise price of $2.44, the options may expire worthless.
• Vesting is subject to continued service, meaning the options could be forfeited if the reporting person ceases to be a service provider before the vesting date.

Future Outlook

This filing primarily reports a past transaction (option grant) and does not provide explicit forward-looking statements or guidance on company performance. The vesting schedule indicates a future commitment for the reporting person's continued service.

Industry Context

This is a standard insider transaction filing (Form 4) for a director receiving equity compensation. It aligns with common practices in the biotechnology/pharmaceutical industry, where equity incentives are used to align director interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to directors is a common form of equity compensation across various industries, including biotechnology.
• The vesting schedule (1 year or next annual meeting) is typical for director equity grants, aiming to retain talent and align interests over a reasonable period.
• The exercise price being a specific value ($2.44) suggests it might be the fair market value at the time of grant, which is standard for incentive stock options.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns the director's financial incentives with the long-term performance of the company's stock, potentially benefiting shareholders if the stock price increases.
• Employees/Management: This is a form of equity compensation, which is a common tool for attracting and retaining key personnel and aligning their interests with company success.

Next Steps

• The options are subject to vesting on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders.
• The reporting person must continue as a service provider through the applicable vesting date to receive the shares.

Key Dates

Keywords

OnKure Therapeutics, OKUR, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership, Valerie Malyvanh Jansen